UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of: December, 2003
Commission File Number: 000-50393
NEUROCHEM INC.
7220 Frederick-Banting, Suite 100
Saint-Laurent, Quebec
H4S 2A1
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
December 11, 2003
By: /s/ David Skinner
--------------------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
[Logo of Neurochem]
NEUROCHEM INC.
7220 Frederick-Banting, suite 100
Saint-Laurent QC H4S 2A1 Canada
FOR IMMEDIATE RELEASE
FRANCESCO BELLINI:
2003 PERSONALITY OF THE YEAR IN BUSINESS CATEGORY
MONTREAL, CANADA, DECEMBER 10, 2003--Dr. Francesco Bellini, chairman and CEO of
Neurochem, has been named Personality of the Year for 2003, in the Business
category, by Cyberpresse.ca, a Montreal-based news Website.
Cyberpresse selected Dr. Bellini because the value of Neurochem's shares has
more than tripled in the past year, making it the best-performing stock in
Quebec this year.
In explaining the choice, Cyberpresse added: "There are several reasons for the
strong performance by Neurochem's shares: first, there are the very positive
consecutive results in clinical trials of its drug against Alzheimer's disease;
then, there was the company's listing on NASDAQ, and lastly, there is Dr.
Bellini's reputation. His former company, Biochem Pharma, discovered the AIDS
drug, 3TC, in the late 1980s."
Dr. Bellini said he was very proud to receive this honour and insisted that
Neurochem owes its success to its management team and employees. "Without a good
business strategy based on the talents of all of our staff, our company could
not have distinguished itself as it is now doing," he said.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's staged pipeline of
proprietary, disease-modifying, oral products addresses critical unmet medical
needs. Fibrillex(TM), designated an orphan drug, is in a Phase II/III clinical
trial for AA amyloidosis. Alzhemed(TM) has completed a Phase II clinical trial
for the treatment of Alzheimer's Disease. Cerebril(TM) is in a Phase II trial
for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy.
For additional information on Neurochem, please visit our Web site at:
www.neurochem.com.
FOR FURTHER INFORMATION:
Dr. Lise Hebert
Vice-president, Corporate Communications
lhebert @neurochem.com
(514) 337-4646
Fax: (514) 337-5339